Literature DB >> 8452656

Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

A K Scott1.   

Abstract

All drugs produce adverse effects, though the risk varies widely between different compounds. Many toxic reactions are an extension of the mechanism responsible for the therapeutic effect and can be avoided by careful dose adjustment. Other adverse events are not related to the beneficial action of the drug. Recent interest has focused on the role of the different properties of individual drug enantiomers in causing drug toxicity. For drugs with a single chiral centre, both enantiomers may be therapeutically active. However, if the main therapeutic benefit is in only 1 enantiomer, several possibilities exist for the other enantiomer--inactive, a qualitatively different effect, an antagonistic effect or greater toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452656     DOI: 10.2165/00002018-199308020-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  34 in total

Review 1.  Chirality in antirheumatic drugs.

Authors:  W F Kean; C J Lock; H E Howard-Lock
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

Review 2.  The treatment of osteoarthritis.

Authors:  A C Jones; M Doherty
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

3.  Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.

Authors:  T Baba; S Murabayashi; K Aoyagi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Age-associated stereoselective alterations in hexobarbital metabolism.

Authors:  M H Chandler; S R Scott; R A Blouin
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

5.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

6.  Enantiomers of warfarin and vitamin K1 metabolism.

Authors:  I A Choonara; B P Haynes; S Cholerton; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 7.  Which beta blocker?

Authors:  A Breckenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-02

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

Review 9.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

10.  Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.

Authors:  H Echizen; B Vogelgesang; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

View more
  7 in total

Review 1.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Pharmacological importance of stereochemical resolution of enantiomeric drugs.

Authors:  M R Islam; J G Mahdi; I D Bowen
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.228

3.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

4.  Chiral liquid chromatography-tandem mass spectrometry analysis of superwarfarin rodenticide stereoisomers - Bromadiolone, difenacoum and brodifacoum - In human plasma.

Authors:  Daniel G Nosal; Douglas L Feinstein; Richard B van Breemen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-01-07       Impact factor: 3.318

Review 5.  Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.

Authors:  Morgan E Rook; Amber L Southwell
Journal:  BioDrugs       Date:  2022-03-07       Impact factor: 7.744

Review 6.  Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic.

Authors:  Waqas Ali; Ahmad Elsahn; Darren S J Ting; Harminder S Dua; Imran Mohammed
Journal:  Antibiotics (Basel)       Date:  2022-04-01

7.  Chiral drugs: an overview.

Authors:  Lien Ai Nguyen; Hua He; Chuong Pham-Huy
Journal:  Int J Biomed Sci       Date:  2006-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.